Because analysis of the RV144 and HVTN 505 trials suggests that the profile of robust envelope specific IgG and IgG3 responses in the absence of certain envelope specific IgA responses correlates inversely with infection risk41,43–46, the ratios of IgG and IgG3 to IgA were calculated. The gene discussed is CD79A; the disease is infection.